Search 

At FJS Biopharmaceutical Inc., we combine technological innovation with world class process excellence. These enable our customers to deliver their discoveries. In our extensive contract development services portfolio we use advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins.

Changes in the global marketplace are quickly altering the demands on biopharmaceutical manufacturing facilities. we have changed to Continuous Manufacturing Processes design that is cost-effective, flexible and responsive to a diversified product line. Continuous manufacturing processes offers a number of advantages:
1. More agile and flexible, and can therefore respond more rapidly to changes in supply or demand.
2. Reducing or eliminating scale-up bottlenecks could also help to accelerate the path to market for breakthrough
pharmaceuticals.
3. More efficient, reliable and cost-effective than traditional batch methods, resulting in significant cost savings down the line.
4. Producing smaller environmental footprint and reduce the risk of product quality failures compared to batch systems.
5. Supports a systematic, scientific and risk-based approach to pharmaceutical development. Development of a robust
process relies on utilizing the acquired product and process understanding to identify sources of variation to product quality
and to design appropriate control strategies to address these risk areas.
6. provides an opportunity to utilize this enhanced product and process understanding to adopt advanced manufacturing
controls and to produce uniformly high-quality products with reduced waste resulting from the generation of out-of-
specification material.

We are a preferred global partner to the Biopharmaceutical, biotech and specialty ingredients markets. Our solutions improve life quality by preventing illness, enabling healthier lifestyles and supporting a safe environment.

Leading healthcare company in china

Engaged in novel protein drug development and commercialization

Guoqian Venture Capital is one of the two business platforms; the other is Guoqian Medical Technology Innovation Research Institute, which is an incubator/accelerator for startup and growth companies.
Guoqian Venture Capital is a professional and market-oriented venture capital firm that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on innovative technologies and products. Due to currency restrictions, the firm can only invest in entities in China. The investment size is from ￥5 million （$750k) to ￥20 million ($ 3 million).
Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in Chinese medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.

A public pharmaceutical company

Hong Kong Biotechnology Organization is an independent nonprofit organization (Charities exempted from tax under Section 88 of the Inland Revenue Ordinance) with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.

Founded in 2017, it has been the mission of Nanjing IASO Biotherapeutics (IASO BIO) to become a leading biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

IASO BIO stands out through innovation, a world class facility, and an internationally renowned clinical research team that has treated more than 400 patients. Curing many who continually failed through multiple-lines of therapy, by means of detailed and thorough pathological analysis and follow up.

IASO BIO is dedicated to curing cancer using engineered autologous/allogenic T cell therapies designed to enhance the immune system's ability to recognize and eradicate cancer cells. Safety is dramatically enhanced via a proprietary procedure, minimizing the severity of CRS. Currently, IASO BIO is developing over 10 high-potential pharmaceutical products, targeting hematological tumors, solid tumors and virus associated tumors at different clinic stages.

Investment Bank